T1	Participants 40 94	in patients with chronic obstructive pulmonary disease
T2	Participants 399 483	patients will require ongoing therapeutic management for many years, or even decades
T3	Participants 728 785	435 adults with stable, symptomatic, smoking-related COPD
T4	Participants 1162 1306	There were a total of 79 patients with serious adverse events (SAEs), 43 (14.8%) in the sibenadet pMDI group and 36 (24.8%) in the placebo group
T5	Participants 1737 1821	patients in the sibenadet group did, however, report reduced rescue medication usage
